Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
CM.9NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
CM.9NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
XBB.4.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.4.1NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
BA.2.59NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.59NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
BR.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BR.2NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
BQ.1.7NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BQ.1.7NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
CM.5.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
CM.5.2NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
XBDNNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBDNNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
EB.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
EB.1NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
XBB.1.10NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.1.10NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
BQ.1.1.61NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BQ.1.1.61NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
BA.5.2.37NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.5.2.37NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
BA.5.2.10NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.5.2.10NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
XASNNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XASNNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
BA.5.3.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.5.3.4NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.396NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.396NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.595.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.595.3NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.2NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.311NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.311NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.369NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.369NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.367NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.367NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.595NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.595NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.240NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.240NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.1.192NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.192NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
JN.1.39.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JN.1.39.1NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
ME.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
ME.1NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used